Top buy and sell ideas by Ashwani Gujral, Mitessh Thakkar, Prakash Gaba for short term

The BSE Sensex fell 100.53 points to 38,132.88 while the Nifty50 declined 38.20 points to 11,445.05 and formed bearish candle on daily charts. The Nifty Midcap and Smallcap indices outperformed frontliners, rising 0.5 percent and 1.24 percent respectively.

Bulls lost their power in last hour of trade on March 27 with the Nifty50 closing tad below 11,450 levels on profit booking ahead of expiry of March futures & options contracts on Thursday.

According to the Pivot charts, the key support level is placed at 11,389.93, followed by 11,334.87. If the index starts moving upward, key resistance levels to watch out are 11,523.13 and 11,601.27.

The Nifty Bank index closed at 30,019.80, up 137.65 points on March 27. The important Pivot level, which will act as crucial support for the index, is placed at 29,785.79, followed by 29,551.8. On the upside, key resistance levels are placed at 30,258.2, followed by 30,496.6.

related news IPL 2019 | RCB vs MI Match 7 preview: Bragging rights at stake as Kohli faces Bumrah Adequate room for RBI to cut interest rates, says Neelkanth Mishra of Credit Suisse

In an interview to CNBC-TV18, top market experts recommend which stocks to bet on for good returns:

Ashwani Gujral of ashwanigujral.com

Buy Escorts with a stop loss of Rs 810, target of Rs 845

Buy Ujjivan Financial Services with a stop loss of Rs 332, target of Rs 347

Buy L&T Finance Holdings with a stop loss of Rs 146, target of Rs 160

Buy ICICI Prudential Life Insurance with a stop loss of Rs 345, target of Rs 362

Buy Jindal Steel & Power with a stop loss of Rs 162, target of Rs 174

Mitessh Thakkar of mitesshthakkar.com

Sell Biocon with a stop loss of Rs 614 and target of Rs 580

Buy Engineers India with a stop loss of Rs 113.5 and target of Rs 124

Buy IDFC with a stop loss of Rs 44.5 and target of Rs 50

Buy L&T Finance Holdings with a stop loss of Rs 148.8 and target of Rs 158

Prakash Gaba of prakashgaba.com

Buy Voltas with target at Rs 640 and stop loss at Rs 614

Buy L&T Finance with target at Rs 155 and stop loss at Rs 149

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com/CNBC-TV18 are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.​ First Published on Mar 28, 2019 08:19 am

There's a Whole New Way to Profit in the Red-Hot Marijuana Sector

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Greg Miller

It's hard to overstate the importance of the 2018 Farm Bill for the American cannabis business – and the folks who've had the foresight to follow along with our cannabis investing research.

As my readers have seen with the market-crushing slew of double-digit gains in our model portfolio, the Farm Bill was like flipping the switch on a money-printing machine.

But there's another, far less well-known law on the books. This is going back to 2012, although it wasn't fully implemented until 2016.

I mean the Jumpstart Our Business Startups (JOBS) Act. It was meant to encourage the funding of small businesses while easing the the burden of regulatory compliance. The Act makes it possible for a business to raise tens of millions of dollars in capital from anyone – a huge boost for most early-stage startups.

No doubt that's great news for America's economy…

… But it's an absolutely earth-shattering development for marijuana investors. It's right up there with federal legalization in terms of unleashing profit potential.

It opens to the door to a galaxy of investing opportunities in the cannabis sector.

So let me show the kinds of profits that are possible when you know how to step right through…

Join the conversation. Click here to jump to comments…

Greg Miller

About the Author

Browse Greg's articles | View Greg's research services

Greg Miller started working on Wall Street in September, 1987, just a month before the "Black Monday" stock market crash.

During his career there, he became an expert in just about every kind of publicly traded security - from blue-chip and small-cap stocks to municipals, junk bonds, and derivatives. As a portfolio manager, Greg was responsible for over $500 million of assets in mutual funds and insurance company accounts.

After leaving the Street, he designed a successful options trading strategy and made lucrative tech investments for a financial publication. He has also helped develop new products and worked with other editors to hone their strategies.  He's always been dedicated to deep, fundamental research - and he always will be - because he believes buying the very best companies at the right price is the best way to amass wealth in the stock market.

… Read full bio

Has The Social Media Vote-Rigging Been Stopped? Brexit Will Be The Test

&l;p&g;&l;img class=&q;dam-image getty wp-image-1136507676 size-large&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1136507676/960x0.jpg?fit=scale&q; alt=&q;&q; data-height=&q;957&q; data-width=&q;960&q;&g;

Once upon a time you could predict the outcome of events by looking at the markets. That all changed and it turned out that the reason markets and bookmakers stopped acting as good indicators on the voters mood was that elections were being &a;lsquo;fixed&a;rsquo; by social media meddling.

By targeting swing voters with &a;rsquo;fake news&a;rsquo; elections that would have gone one way went another and mainstream polls didn&a;rsquo;t pick this up because it was only the tiny focal point of these campaigns that made the difference, which was invisible to the mass.

These series of upsets are clear and one of them is likely to be the Brexit vote.

You might say these tactic are no different than other political advertising which too are laced with lies and manipulation and that is in a way true. However, there is something very sinister about stalking individuals by using their social media footprint and then feeding them lies that play on their fears to get them to vote a certain way.

Once the penny dropped that this was going on the scandal of it shocked anybody who cares to fear the likes of Cambridge Analytics rigging elections.

The question now is, has this been stopped?

We are about to find out with Brexit.

The stock market seems to think we are in for a soft or no Brexit result. The book makers see no likelihood of a Hard Brexit.

&l;img class=&q;size-full wp-image-59637&q; src=&q;http://blogs-images.forbes.com/investor/files/2019/03/ftsebrexit190319.jpg?width=960&q; alt=&q;The stock market doesn&s;t think we will have a Hard Brexit&q; data-height=&q;589&q; data-width=&q;900&q;&g; The stock market doesn&s;t think we will have a Hard Brexit

Here are the odds:

&l;/p&g;&l;div class=&q;table-wrapper&q;&g;&l;table&g;&l;tbody&g;&l;tr&g;&l;td width=&q;350&q;&g;Brexit second referendum&l;/td&g; &l;td width=&q;77&q;&g;5/2&l;/td&g; &l;/tr&g;&l;tr&g;&l;td width=&q;350&q;&g;Article 50 extension&l;/td&g; &l;td width=&q;77&q;&g;1/6 on&l;/td&g; &l;/tr&g;&l;tr&g;&l;td width=&q;350&q;&g;Hard Brexit&l;/td&g; &l;td width=&q;77&q;&g;5/1&l;/td&g; &l;/tr&g;&l;tr&g;&l;td width=&q;350&q;&g;Brexit date this year &a;ndash; even money&l;/td&g; &l;td width=&q;77&q;&g;50/50&l;/td&g; &l;/tr&g;&l;tr&g;&l;td width=&q;350&q;&g;Second UK referendum and votes to remain&l;/td&g; &l;td width=&q;77&q;&g;4/1&l;/td&g; &l;/tr&g;&l;/tbody&g;&l;/table&g;&l;/div&g;

So the market says soft Brexit and so do the bookies.

The punters say, Article 50 extension, Brexit this year, no Hard Brexit and no second referendum.

Personally, I&a;rsquo;d take the second referendum bet and the Hard Brexit bet if I was a gambling man. The odds are good even if it doesn&a;rsquo;t turn out that way. Luckily for me I am not a betting man.

So if you believe in markets as oracles and then the stock market indication and the bookmaker odds turn out totally wrong, again, then we might rest easy that the political data-miners are not the reason the last election&a;rsquo;s results were such a surprise to the markets and oddsmakers.

If these informal pollsters get it right this time, as they used to before the sinister phenomena of social media data and &a;lsquo;fake news&a;rsquo; raised its ugly head, it&a;rsquo;s another warning that social media manipulation of public opinion and voting is very real. When it comes to polls if there are forces at work manipulating the vote away from the wisdom of the crowd to the benefit of those with the best data and algos then we are in great peril.

Of all the dangers to our freedom and democracy the perils of the covert manipulation of the public vote is the paramount danger.

&a;nbsp;

&l;em&g;Clem Chambers is the CEO of leading private investors Web site&l;/em&g;&l;span&g;&l;em&g;&a;nbsp;&l;/em&g;&l;/span&g;&l;a href=&q;http://www.advfn.com/&q; target=&q;_blank&q;&g;&l;em&g;ADVFN.com&l;/em&g;&l;/a&g;&l;em&g; and author of &l;/em&g;&l;a href=&q;http://www.amazon.com/dp/B00R3ABO9G&q; target=&q;_blank&q;&g;Be Rich&l;/a&g;&l;em&g;, &l;/em&g;&l;a href=&q;http://www.amazon.com/dp/B00HCOUWS2&q; target=&q;_blank&q;&g;&l;em&g;The Game in Wall Street&l;/em&g;&l;/a&g;&l;em&g; and&l;/em&g; &l;a href=&q;https://www.amazon.com/dp/B077D9ZZ7P&q; target=&q;_blank&q;&g;&l;em&g;Trading Cryptocurrencies: A Beginner&a;rsquo;s Guide&l;/em&g;&l;/a&g;&l;em&g;, out now in paperback and on the Kindle. &l;/em&g;

Insider Selling: Abbott Laboratories (ABT) Insider Sells 9,188 Shares of Stock

Abbott Laboratories (NYSE:ABT) insider Roger Bird sold 9,188 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $79.06, for a total value of $726,403.28. Following the sale, the insider now owns 60,195 shares in the company, valued at $4,759,016.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NYSE ABT traded up $0.36 during trading hours on Thursday, reaching $78.98. 5,382,111 shares of the stock traded hands, compared to its average volume of 6,356,053. The stock has a market cap of $137.43 billion, a price-to-earnings ratio of 27.42, a P/E/G ratio of 2.09 and a beta of 1.13. The company has a current ratio of 1.62, a quick ratio of 1.20 and a debt-to-equity ratio of 0.63. Abbott Laboratories has a 52-week low of $56.81 and a 52-week high of $79.14.

Get Abbott Laboratories alerts:

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.81. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.82 billion. Abbott Laboratories had a return on equity of 16.55% and a net margin of 7.74%. Abbott Laboratories’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $0.74 EPS. On average, analysts forecast that Abbott Laboratories will post 3.2 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.62%. Abbott Laboratories’s dividend payout ratio is 44.44%.

Several hedge funds and other institutional investors have recently made changes to their positions in ABT. First Trust Advisors LP grew its position in shares of Abbott Laboratories by 30.2% in the 3rd quarter. First Trust Advisors LP now owns 56,019 shares of the healthcare product maker’s stock worth $4,110,000 after buying an additional 12,978 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Abbott Laboratories by 49.8% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 365,246 shares of the healthcare product maker’s stock worth $26,794,000 after buying an additional 121,364 shares during the last quarter. WINTON GROUP Ltd grew its position in shares of Abbott Laboratories by 58.5% in the 3rd quarter. WINTON GROUP Ltd now owns 9,540 shares of the healthcare product maker’s stock worth $700,000 after buying an additional 3,520 shares during the last quarter. Forbes J M & Co. LLP grew its position in shares of Abbott Laboratories by 1,508.3% in the 3rd quarter. Forbes J M & Co. LLP now owns 144,636 shares of the healthcare product maker’s stock worth $10,611,000 after buying an additional 135,643 shares during the last quarter. Finally, Virginia Retirement Systems ET AL grew its position in shares of Abbott Laboratories by 52.3% in the 3rd quarter. Virginia Retirement Systems ET AL now owns 283,200 shares of the healthcare product maker’s stock worth $20,776,000 after buying an additional 97,200 shares during the last quarter. 74.31% of the stock is currently owned by institutional investors.

ABT has been the topic of a number of research analyst reports. Wells Fargo & Co restated a “buy” rating on shares of Abbott Laboratories in a report on Thursday. Credit Suisse Group initiated coverage on Abbott Laboratories in a research report on Monday, December 17th. They issued an “outperform” rating and a $82.00 price target for the company. Argus increased their price target on Abbott Laboratories to $90.00 and gave the company an “in-line” rating in a research report on Friday, January 25th. They noted that the move was a valuation call. Barclays set a $84.00 price target on Abbott Laboratories and gave the stock a “buy” rating in a research note on Friday, March 8th. Finally, Morgan Stanley raised their target price on Abbott Laboratories from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. Abbott Laboratories has a consensus rating of “Buy” and a consensus target price of $79.71.

ILLEGAL ACTIVITY WARNING: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/4221581/insider-selling-abbott-laboratories-abt-insider-sells-9188-shares-of-stock.html.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Featured Story: Diversification in Investing

Why Aurora's Latest Strategy Smells Like Desperation

Aurora Cannabis (NYSE:ACB) recently made a silly attempt to convince investors they could look forward to adults making smart decisions in the boardroom, and it worked. Shares of Aurora finished Wednesday's session 13.9% higher because the company hired an activist investor to set up some meetings with large consumer-goods companies eager to make a deal. 

If you don't understand why this investor relations stunt isn't worth a press release, you need to read this now. 

What activist investors do

Activist investors generally run large funds that take large stakes in a company's stock in an attempt to wield influence over it. This is often a CEO's worst nightmare, but for everyday investors like us, it can be a dream come true.

How CEOs normally feel when an activist investor takes interest in their company. Image source: Getty Images.

For example, Jana Partners is an activist hedge fund that took up an 8% stake in Whole Foods in early 2017. That was enough to get the ball rolling and gather together shareholders who wanted the struggling grocer to put itself up for sale. Within a few months, Amazon.com swooped in with $13.7 billion in cash, which immediately raised Whole Foods' stock price 28% higher.

Whole Foods CEO John Mackey called Jana Partners "greedy bastards," but the struggling grocer's investors are probably better off.

Who hires an activist to act as an advisor? 

Generally, activists try to help shareholders by getting management to do something it doesn't want to do in the first place. Hiring one as an advisor is pointless.

That didn't stop enthusiastic investors from piling in after Aurora Cannabis told investors that Nelson Peltz, a well-known activist investor with a great deal of food distribution experience, is officially a part of Aurora's management team as a "senior strategic advisor." Although Peltz is the CEO of Trian Fund Management, his fund hasn't disclosed any investment stake in Aurora Cannabis.

If Trian Fund doesn't own a piece of the company, Aurora's managers don't have to take the advice they're paying Peltz to provide. Despite slim odds that this partnership will produce more than a press release, Aurora Cannabis' market cap rose by roughly $1 billion on the day of the announcement.

Image source: Getty Images.

Now you want advice?

Peltz and Aurora will work on finding partnerships and expanding the company's global footprint, but those boats sailed a long time ago. Between August 2016 and December 2018, Aurora Cannabis undertook 15 acquisitions and made investments into 12 others. Now that the company has already expanded operations to 24 separate countries at great expense, any more expanding before we have proof these markets are viable seems like a bad idea.  

If Peltz were given a board seat, he would most likely put an end to the dilutive acquisitions that have already made it impossible for long-term Aurora shareholders to realize a decent return. This company has been using its own shares to expand at all costs, which is a lot more expensive than most investors realize.

Aurora Cannabis stock has risen an exciting 396% over the past two years, but most investors have overlooked the number of new shares the company's created to keep everyone interested. Over the same time frame, the number of outstanding shares nearly tripled. To provide the return investors were hoping for, profits needed to rise three times higher than investors were expecting.

Strategy lessons from this guy?

Peltz is a well known activist investor, but not because he's been particularly successful lately. In 2015, his fund poured $2.5 billion into General Electric (NYSE:GE), and shares of the conglomerate have underperformed the S&P 500 by 86% since Trian Fund Management disclosed its stake.

Shortly after pulling the trigger on GE, the Trian Fund opened a position in Procter & Gamble (NYSE:PG) that's become its largest at $3.5 billion. A decade ago, P&G had a handful of competitors that could even dream of launching a new brand of men's razor. Now, the big consumer-goods companies are all scrambling to buy start-ups that are competing in ways that just weren't possible a very short time ago.  

Experienced cannabis consumers in Canada already know that Aurora's brands can't compete with their favorite mom-and-pop operations in terms of quality. Try to imagine a can of Budweiser versus a fresh pint of ale at the brewery it was born in. The big difference is that small-batch marijuana tends to be significantly less expensive.

Peltz is having a rough time with P&G's established brands, but that's nothing compared to the challenges ahead of Aurora. The company's attempt to build brands in heavily taxed markets, with competition from untaxed illicit markets breathing down its neck, is going to be an uphill slog.

Image source: Getty Images.

What Peltz could bring to the table

Nearly every week, at least one marijuana stock rises after the company announces an all-stock purchase decision that would send stocks from any other industry tumbling. The marijuana industry isn't going to stop partying like it's the internet in 1999, and Peltz isn't going to stop Aurora from using its shares the way my son uses Monopoly money.

Aurora's stunt smells like desperation, but paying Peltz to be an advisor does bring an air of partnership possibility to Aurora's image that someone might find appealing. Hoping another desperate company with failing brands makes a bad decision, though, isn't a very good investing strategy. 

Roku Shares Hit With 2 Downgrades

So far in 2019, shares of streaming TV platform Roku (NASDAQ:ROKU) have staged a massive comeback, gaining 131% year to date through yesterday's close. The stock is now nearly back to where it was before the broad market turmoil in the fourth quarter. To be clear, Roku has given investors a lot to be optimistic about in recent months. Core operating metrics like active accounts, hours streamed, and average revenue per user (ARPU) all continue to march into record territory, and Roku expects to hit $1 billion in revenue this year, a significant milestone for the company.

But the market could be getting ahead of itself.

Image source: Roku.

A tale of two downgrades

Roku was hit with two separate downgrades today, thanks to Loop Capital and Macquarie, with analysts at both firms pointing to stretched valuation at current levels.

Loop Capital dropped its rating on Roku shares from hold to sell, while keeping a $45 price target. Analyst Alan Gould argues that the stock has reached "excessive valuation" levels and believes Roku could suffer from intensifying competition on the horizon. The streaming wars are heating up, with a multitude of traditional telecom and media giants bringing over-the-top (OTT) services to market this year. That could help Roku's hardware business, even while putting competitive pressure on the platform segment.

Gould also notes that there has been an uptick in insider selling, which doesn't inspire a lot of confidence. For example, regulatory filings show CEO Anthony Wood converted and sold 35,000 shares earlier this month as part of a pre-arranged Rule 10b5-1 trading plan at prices between $66.81 and $69.82. Roku also filed a mixed shelf offering this week for an unspecified number of shares, suggesting some dilution is in store.

Separately, Macquarie downgraded its rating on Roku to neutral, similarly pointing to "a full valuation" at current levels. Beyond the upcoming onslaught of traditional companies jumping into the streaming space, Macquarie is also concerned about Apple's upcoming video-streaming service, which will be unveiled in less than two weeks. That service could garner 100 million subscribers within a few years of launch, according to estimates from Wedbush.

Macquarie is also concerned that Roku's ad business could get hurt, as the media giants are now collaborating on a new consortium led by TV manufacturer Vizio called Project OAR, which stands for "Open Addressable Ready." The goal is to create an open standardized advertising platform for the industry's ongoing shift to streaming, facilitating targeted ads akin to how online ad networks are able to target eyeballs with uncanny accuracy. That initiative was just announced this week and isn't expected to officially launch until next year, but it could eventually threaten to undermine Roku's proprietary ad platform and poach advertisers.

Roku's platform segment is largely driven by advertising, with revenue sharing of subscription and a-la-carte purchases representing a smaller portion of that business. Much of Roku's ARPU gains -- which are calculated as total platform revenue divided by active accounts on a trailing-12-month (TTM) basis -- are attributable to growth in advertising revenue. ARPU hit a record $17.95 in 2018.

Roku is facing many potential headwinds going forward, and intensifying competition combined with a lofty valuation is a recipe for a pullback.

Igloo recalls select coolers after boy locked…

Igloo Products Corp. is voluntarily recalling coolers from its Marine Elite line after reports that a Florida boy was trapped inside one.

According to WSVN, 5-year-old Nicholas Wanes climbed inside his family's 72-quart Marine Elite cooler on March 2. The Florida news station reports that he was in the cooler playing hide-and-seek with the lid open before it shut and he was locked in.

Nicholas' father, Robert Wanes of Pompano Beach, said in a Facebook post that his security camera caught the incident, which he posted on March 5.

"So we always see the good stuff and although this story ended well, hopefully there is something to be learned," Robert Wanes wrote in the post. "My son Nicholas got locked inside an igloo cooler. He was playing by himself and thought it was a good idea."

After the incident, Igloo issued a safety alert on its website announcing the voluntary recall that identifies eight models and item numbers, four of which the company says were sold at West Marine.

"It is possible that the stainless-steel latch could, inadvertently close where a person could potentially become locked inside," the safety alert states.

.oembed-frame { width: 100%; height: 100%; margin: 0; border: 0; }

Pasta recall: Chef Boyardee recalls beef ravioli bowls mislabeled as rice with chicken and veggies

Drug recall: 126 lots of popular blood pressure medication recalled for cancer risk

"We stand behind the quality of our products, and because your safety and satisfaction are our top priority, we wanted to let you know that we are voluntarily recalling the Igloo Marine Elite coolers," Igloo said in a statement on its website. "This recall concerns only those Igloo Marine Elite coolers with stainless-steel ability to lock latches."

The affected items are:

Igloo Marine Elite 72 quart; Item #00049375Igloo Marine Elite 54 quart; Item #00049374Igloo Marine Elite 94 quart; Item #00049574Igloo Marine Elite 110 quart; Item #00034108Igloo Marine Elite 72 quart; Item #00044476 (West Marine)Igloo Marine Elite 128 quart; Item #00044479 (West Marine)Igloo Marine Elite 94 quart; Item #00044478 (West Marine)Igloo Marine Elite 162 quart; Item #00044480 (West Marine)

The latch-replacement kits have been sent to some customers, but those who haven't received a kit can call Igloo at 866-509-3503. 

"We sincerely apologize for any inconvenience this issue may have caused you," Igloo said in the statement. "Our goal is to do everything we can to get you back out on the water using and loving your Igloo cooler."

Igloo did not immediately respond to USA TODAY's request for comment.

Follow Kelly Tyko on Twitter: @KellyTyko

FacebookTwitterGoogle+LinkedInThe day in pictures FullscreenPost to FacebookPosted!

A link has been posted to your Facebook feed.

Bus ushers walk past red flags on Tiananmen Square during a plenary session of the Chinese People's Political Consultative Conference at the Great Hall of the People in Beijing. Ng Han Guan, APFullscreenMourners attend a memorial service in Addis Ababa, Ethiopia. Authorities in Ethiopia, China and Indonesia grounded all Boeing 737 Max 8 aircraft Monday following the crash of an Ethiopian Airlines jetliner that killed 157 people. Samuel Habtab, APFullscreenFormer Trump campaign foreign policy advisor George Papadopoulos and his wife Simona Mangiante walk through the Hart Senate Office Building in Washington, DC. Mangiante was scheduled to meet with the Senate Intelligence Committee. Mark Wilson, Getty ImagesFullscreenRevellers participate in a carnival procession in Basel, Switzerland. GEORGIOS KEFALAS, EPA-EFEFullscreenKashmiris flee their villages after one person was killed and three others were injured as Indian forces fired mortar shells from across the Line of Control, at the border between Pakistani and Kashmir. AMIRUDDIN MUGHAL, EPA-EFEFullscreenA boy picks up a burning wooden disc for the traditional 'Scheibenschlagen', in Plattis, Switzerland. In this tradition a glowing disc of wood, dedicated to a loved person, is hurled towards the valley and on the same day, the so-called "Funkensonntag", a big fire is lit to drive winter away. GIAN EHRENZELLER, EPA-EFEFullscreenHot air balloons are seen rising over Lake Burley-Griffin during the Canberra International Balloon festival in Canberra, Australia. The festival is considered one of the biggest hot air balloon festivals in the world. LUKAS COCH, EPA-EFEFullscreenA woman protects herself as she walks during an unexpected snowfall in Minsk, Belarus. Sergei Grits, APFullscreenPoeple fly kites on Filopappou hill overlooking the ancient Acropolis in Athens. "Clean Monday" marks the end of the carnival and the start of the 40-day fasting period of Lent, leading up to Orthodox Easter. LOUISA GOULIAMAKI, AFP/Getty ImagesFullscreenIndonesian Siti Aisyah waves after a press conference in Jakarta. Shock and delight rippled through the Indonesian town of Sindangsari as residents got word that a local woman accused of assassinating the North Korean leader's half-brother had been freed. ADEK BERRY, AFP/Getty ImagesFullscreenThis is the construction site with the world's tallest tower Burj Khalifa (background) in the Gulf emirate of Dubai. KARIM SAHIB, AFP/Getty ImagesFullscreenLee Spencer, a 49-year-old former British marine, known as 'The Rowing Marine', holds a red flare and his prosthesis as he arrives in Cayenne, French Guiana after smashing solo Atlantic rowing record from mainland Europe to South America. Spencer spent 60 days offshore to cross the Atlantic through 3,800 nautical miles, becoming the first physically disabled person to make the solo crossing. JODY AMIET, AFP/Getty ImagesFullscreenInterested in this topic? You may also want to view these photo galleries:Replay1 of 122 of 123 of 124 of 125 of 126 of 127 of 128 of 129 of 1210 of 1211 of 1212 of 12AutoplayShow ThumbnailsShow CaptionsLast SlideNext Slide

 

Top 10 Heal Care Stocks To Buy Right Now

tags:KONE,EGL,COL,IPHI,KMG,SEM,AMRN,NTP,VAL,IMKTA,

For our top pick in 2017, I used my guru-based screening application to look for stocks with high scores from at least two of my guru models, explains John Reese, editor of Validea.

I focused on fundamental strategies based on Buffett, Graham, Lynch, Zweig, Neff and a number of others and stocks with the lowest relative strength, meaning the stocks that have underperformed the most over the past 12 months.

Since this is an aggressive pick, we can look for a name that looks to be extremely oversold and being priced for a worst case scenario.

These are the types of stocks that Ben Graham called cigar butt stocks in the sense that you may be able to pick them up and take one last, but really good puff and get it for virtually free.

One of the stocks that meets this criteria is GNC Holdings (GNC), an $890 million specialty retailer of health, wellness and performance products.

Top 10 Heal Care Stocks To Buy Right Now: Kingtone Wirelessinfo Solution Holding Ltd(KONE)

Advisors' Opinion:

• [By Money Morning News Team]

  While a 209% gain is exciting, FunctionX's gains are in the past. After looking at the 10 top penny stocks to watch this week, we'll show you a small-cap stock with serious profit potential ahead of it…

  Penny Stock Current Share Price Law Week's Gain FunctionX Inc. (OTCMKTS: FNCX) $0.03 209% Turtle Beach Corp. (Nasdaq: HEAR) $4.48 52.73% DPW Holdings Inc. (NYSE: DPW) $1.16 51.31% Energy XXI Gulf Coast Inc. (Nasdaq: EGC) $5.62 49.33% MYnd Analytics Inc. (Nasdaq: MYND) $1.91 49.21% Kingtone Wirelessinfo Solutions Holding Ltd. (Nasdaq: KONE) $6.43 48.42% Rennova Health Inc. (OTCMKTS: RNVA) $0.02 44.30% International Tower Hill Mines Ltd. (NYSE: THM) $0.72 41.64% Blonder Tongue Labs Inc. (NYSE: BDR) $1.13 41.14% Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM) $8.87 40.53%

  As the gains above suggest, penny stocks can provides tremendous returns for investors very quickly. However, it's important to note that investing in penny stocks is also inherently risky.

Top 10 Heal Care Stocks To Buy Right Now: Engility Holdings, Inc.(EGL)

Advisors' Opinion:

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Engility (EGL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Daniel Sparks]

  The stock's decline followed SAIC's better-than-expected second-quarter results, as well as an announcement from SAIC that it's acquiring Engility Holdings (NYSE:EGL), a staffing and outsourcing services company. The acquisition, which is valued at $2.5 billion when including the assumption of Engility's $900 million in debt, is a significant undertaking given that SAIC's total market capitalization is only around $3.5 billion.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Engility (EGL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Engility (EGL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Heal Care Stocks To Buy Right Now: Rockwell Collins, Inc.(COL)

Advisors' Opinion:

• [By Stephan Byrd]

  Rockwell Collins, Inc. (NYSE:COL) saw some unusual options trading activity on Tuesday. Stock investors bought 1,159 call options on the stock. This represents an increase of 1,367% compared to the typical daily volume of 79 call options.

• [By Lee Samaha]

  Investors in United Technologies (NYSE:UTX) should prepare for some pretty big changes at the conglomerate. It's been a long time coming, but the company's acquisition of Rockwell Collins (NYSE:COL) should be completed by the end of September, and within a couple of months, management will publicly outline the results of its review of strategic options. They are widely expected to deliver a breakup plan. Here's the lowdown, and why splitting up the business makes sense.

• [By Lee Samaha]

  Meanwhile, UTAS reported yet another strong quarter of growth in commercial aftermarket, and with the forthcoming addition of Rockwell Collins (NYSE:COL), UTAS is well positioned to benefit from a buoyant commercial aerospace market.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Rockwell Collins (COL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

  Get Rockwell Collins alerts: Military Avionics Systems Market by leading Industry Players (Avidyne, GE Aviation, Honeywell, Rockwell Collins) and Growth Rate (2018-2025) (emailwire.com) Program aims to connect Maryland’s college students and international businesses (msn.com) Rockwell Collins (COL) Expected to Announce Earnings of $1.89 Per Share (americanbankingnews.com) KAI and Rockwell Collins team up for Korean Chinook upgrade (janes.com) German auto giant boosts bet on cutting-edge AR from Silicon Valley (finance.yahoo.com)

  Several research firms have commented on COL. Royal Bank of Canada reiterated a “hold” rating and issued a $143.00 price objective on shares of Rockwell Collins in a report on Friday, April 6th. Zacks Investment Research downgraded shares of Rockwell Collins from a “buy” rating to a “hold” rating in a research note on Thursday, February 22nd. Cowen restated a “hold” rating and issued a $135.00 price target on shares of Rockwell Collins in a research note on Friday, January 26th. Finally, Canaccord Genuity decreased their price target on shares of Rockwell Collins from $140.00 to $137.00 and set a “hold” rating on the stock in a research note on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $134.13.

Top 10 Heal Care Stocks To Buy Right Now: Inphi Corporation(IPHI)

Advisors' Opinion:

• [By ]

  There are some companies that have weak fundamentals and are regularly incurring losses but that are valued strongly by the market purely based on one metric: revenue growth. Inphi Corporation (NYSE:IPHI) is the perfect example of such a company that has enjoyed a very high valuation despite being a loss-making unit for a large period within the past five years. The company's revenue growth was phenomenal and the profits were expected soon. In fact, the company did end up with a good profit in 2016 when the EV/Sales multiple shot up above 7.

• [By Max Byerly]

  News coverage about Inphi (NYSE:IPHI) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inphi earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the semiconductor company an impact score of 46.0564611984507 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

• [By Max Byerly]

  Get a free copy of the Zacks research report on Inphi (IPHI)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  Inphi Co. (NYSE:IPHI) VP Ron Torten sold 12,342 shares of Inphi stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $35.00, for a total value of $431,970.00. Following the sale, the vice president now directly owns 64,386 shares of the company’s stock, valued at approximately $2,253,510. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

• [By Timothy Green]

  Shares of Inphi Corp. (NYSE:IPHI) dropped on Wednesday following a mixed first-quarter report and a subsequent analyst downgrade. The company's revenue declined sharply and came in just short of analyst expectations. The stock was down about 9.5% at 2:45 p.m. EDT.

• [By Paul Ausick]

  Inphi Corp. (NYSE: IPHI) fell about 8.6% Friday to post a new 52-week low of $32.36 after closing at $35.40 on Thursday. The 52-week high is $51.78. Volume of about 3 million was roughly five times the daily average of around 680,000 shares traded. The company had no specific news.

Top 10 Heal Care Stocks To Buy Right Now: KMG Chemicals, Inc.(KMG)

Advisors' Opinion:

• [By Joseph Griffin]

  Morgan Dempsey Capital Management LLC lowered its stake in KMG Chemicals, Inc. (NYSE:KMG) by 57.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,424 shares of the specialty chemicals company’s stock after selling 20,490 shares during the period. Morgan Dempsey Capital Management LLC owned 0.10% of KMG Chemicals worth $925,000 at the end of the most recent quarter.

• [By Shane Hupp]

  Huntsman (NYSE: KMG) and KMG Chemicals (NYSE:KMG) are both basic materials companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

• [By Motley Fool Staff]

  KMG Chemicals (NYSE:KMG) Q3 2018 Earnings Conference CallJun. 11, 2018 5:00 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

Top 10 Heal Care Stocks To Buy Right Now: Select Medical Holdings Corporation(SEM)

Advisors' Opinion:

• [By Stephan Byrd]

  Strs Ohio boosted its position in Select Medical Holdings Co. (NYSE:SEM) by 5.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,500 shares of the health services provider’s stock after buying an additional 3,300 shares during the quarter. Strs Ohio owned 0.05% of Select Medical worth $1,225,000 at the end of the most recent quarter.

• [By ]

  Cramer was bearish on Oclaro (OCLR) , Stratasys (SSYS) , Washington Prime Group (WPG) and Select Medical Holdings (SEM) .

  No-Huddle Offense 

  In his "No-Huddle Offense" segment, Cramer proclaimed that it's a fallacy to think that a low price/earnings multiple always means a stock is too cheap. Sometimes, the earnings estimates are simply too high.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Select Medical (SEM)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  Get a free copy of the Zacks research report on Select Medical (SEM)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  Highbridge Capital Management LLC acquired a new stake in shares of Select Medical Holdings Co. (NYSE:SEM) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 166,839 shares of the health services provider’s stock, valued at approximately $2,878,000. Highbridge Capital Management LLC owned 0.12% of Select Medical at the end of the most recent quarter.

• [By Ethan Ryder]

  Select Medical Holdings Co. (NYSE:SEM) insider Scott A. Romberger sold 5,000 shares of Select Medical stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $18.63, for a total transaction of $93,150.00. Following the completion of the transaction, the insider now directly owns 158,485 shares of the company’s stock, valued at $2,952,575.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Top 10 Heal Care Stocks To Buy Right Now: Amarin Corporation PLC(AMRN)

Advisors' Opinion:

• [By Beth McKenna]

  Amarin (NASDAQ:AMRN) stock gained 28.6% in January, according to data from from S&P Global Market Intelligence. For context, the the S&P 500 returned 8% last month.

• [By Cory Renauer]

  None of these biotech stocks are tiny, but they're still small enough to produce the dramatic gains this industry is known for. Here's what you need to know about the catalysts heading their way.

  Company (Symbol) Market Cap Candidate Trial Amarin Corporation plc (NASDAQ:AMRN) $966 million Vascepa Reduce-IT Geron Corporation (NASDAQ:GERN) $1.1 billion Imetelstat IMbark  Omeros Corporation (NASDAQ:OMER) $1.3 billion OMS721 IgA

  Data source: Yahoo! Finance, company filings.

• [By Dan Caplinger]

  The stock market came into the new week on a negative note, with the Dow Jones Industrial Average seeing the biggest declines among the major benchmarks. Renewed trade fears and political concerns out of Washington seemed to worry investors, and some trepidation about the speed with which interest rates have risen in recent days also weighed on some portions of the market. Yet some individual companies had good news that sent their shares higher despite the downbeat mood generally. Barrick Gold (NYSE:ABX), Amarin (NASDAQ:AMRN), and California Resources (NYSE:CRC) were among the best performers on the day. Here's why they did so well.

• [By Stephan Byrd]

  Amarin Co. plc (NASDAQ:AMRN)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $3.05, but opened at $3.16. Amarin shares last traded at $3.29, with a volume of 6172422 shares changing hands.

Top 10 Heal Care Stocks To Buy Right Now: Nam Tai Property Inc.(NTP)

Advisors' Opinion:

• [By Ethan Ryder]

  News coverage about Nam Tai Property (NYSE:NTP) has trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nam Tai Property earned a news impact score of 0.20 on Accern’s scale. Accern also gave news coverage about the electronics maker an impact score of 47.3059674665332 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Top 10 Heal Care Stocks To Buy Right Now: Valspar Corporation (VAL)

Advisors' Opinion:

• [By Shane Hupp]

  Shares of ValiRx Plc (LON:VAL) rose 5.6% during mid-day trading on Thursday . The company traded as high as GBX 1.90 ($0.02) and last traded at GBX 1.90 ($0.02). Approximately 587,748 shares were traded during trading, a decline of 85% from the average daily volume of 3,820,000 shares. The stock had previously closed at GBX 1.80 ($0.02).

• [By Max Byerly]

  Valorbit (CURRENCY:VAL) traded 0% higher against the dollar during the 1 day period ending at 11:00 AM Eastern on June 9th. One Valorbit coin can currently be bought for approximately $0.0001 or 0.00000001 BTC on exchanges. Valorbit has a market cap of $537,598.00 and $0.00 worth of Valorbit was traded on exchanges in the last 24 hours. In the last seven days, Valorbit has traded up 5.8% against the dollar.

• [By Stephan Byrd]

  Valorbit (CURRENCY:VAL) traded up 0% against the U.S. dollar during the 1 day period ending at 0:00 AM E.T. on June 18th. One Valorbit coin can now be bought for approximately $0.0001 or 0.00000001 BTC on popular exchanges. Valorbit has a total market capitalization of $537,598.00 and $0.00 worth of Valorbit was traded on exchanges in the last day. During the last week, Valorbit has traded 5.8% higher against the U.S. dollar.

Top 10 Heal Care Stocks To Buy Right Now: Ingles Markets Incorporated(IMKTA)

Advisors' Opinion:

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Ingles Markets (IMKTA)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  BidaskClub lowered shares of Ingles Markets (NASDAQ:IMKTA) from a buy rating to a hold rating in a research report report published on Tuesday.

  IMKTA has been the topic of several other reports. Zacks Investment Research cut shares of Ingles Markets from a hold rating to a sell rating in a research note on Wednesday, August 15th. ValuEngine raised shares of Ingles Markets from a strong sell rating to a sell rating in a research note on Tuesday, July 31st.

• [By Stephan Byrd]

  News articles about Ingles Markets (NASDAQ:IMKTA) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ingles Markets earned a news impact score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.3498595843486 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

• [By Ethan Ryder]

  Ingles Markets, Incorporated (NASDAQ:IMKTA) declared a quarterly dividend on Tuesday, July 3rd, Wall Street Journal reports. Investors of record on Thursday, July 12th will be given a dividend of 0.165 per share on Thursday, July 19th. This represents a $0.66 dividend on an annualized basis and a dividend yield of 2.04%. The ex-dividend date of this dividend is Wednesday, July 11th.

Controladora Vuela Co Avcn SA CV (VLRS) Lifted to Buy at Goldman Sachs Group

Goldman Sachs Group upgraded shares of Controladora Vuela Co Avcn SA CV (NYSE:VLRS) from a sell rating to a buy rating in a report issued on Tuesday, Marketbeat Ratings reports.

Several other research firms have also recently weighed in on VLRS. Deutsche Bank upgraded shares of Controladora Vuela Co Avcn SA CV from a hold rating to a buy rating in a report on Monday, February 25th. Imperial Capital upgraded shares of Controladora Vuela Co Avcn SA CV from an underperform rating to an outperform rating and lifted their price target for the company from $4.50 to $11.50 in a report on Tuesday, February 26th. ValuEngine cut shares of Controladora Vuela Co Avcn SA CV from a buy rating to a hold rating in a report on Friday, March 1st. Zacks Investment Research upgraded shares of Controladora Vuela Co Avcn SA CV from a strong sell rating to a hold rating in a report on Saturday, January 19th. Finally, UBS Group upgraded shares of Controladora Vuela Co Avcn SA CV from a sell rating to a neutral rating in a report on Thursday, January 17th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $8.54.

Get Controladora Vuela Co Avcn SA CV alerts:

NYSE:VLRS opened at $8.78 on Tuesday. The firm has a market capitalization of $858.07 million, a P/E ratio of -25.09 and a beta of 1.03. Controladora Vuela Co Avcn SA CV has a twelve month low of $4.87 and a twelve month high of $9.11.

Institutional investors and hedge funds have recently bought and sold shares of the company. Zacks Investment Management purchased a new position in shares of Controladora Vuela Co Avcn SA CV in the 4th quarter worth about $62,000. Stevens Capital Management LP purchased a new position in shares of Controladora Vuela Co Avcn SA CV in the 4th quarter worth about $73,000. Virtu Financial LLC purchased a new position in shares of Controladora Vuela Co Avcn SA CV in the 4th quarter worth about $139,000. First Mercantile Trust Co. purchased a new position in shares of Controladora Vuela Co Avcn SA CV in the 4th quarter worth about $323,000. Finally, Pendal Group Ltd purchased a new position in shares of Controladora Vuela Co Avcn SA CV in the 3rd quarter worth about $723,000.

Controladora Vuela Co Avcn SA CV Company Profile

Controladora Vuela Compañía de Aviación, SAB. de C.V. provides air transportation services for passengers, cargo, and mail in Mexico and internationally. As of December 31, 2017, the company operated a fleet of 71 Airbus narrow-body aircraft, which include 12 Airbus A319s, 44 A320s, and 10 A321s. It operates approximately 319 daily flight segments on routes that connect 40 cities in Mexico and 27 cities in the United States and Central America.

Further Reading: Hedge Funds

Is DexCom a Buy?

DexCom (NASDAQ:DXCM) has been a home run stock for early investors. Its shares have thrashed the S&P 500 over the last one, three, and five years, showing no signs of slowing.

Can this winner keep thriving? Let's dig into the bull and bear cases for the California-based company to find out.

The business

DexCom, a medical device company focused on diabetes, sells a popular continuous glucose monitor (CGM) system called the DexCom G6. This device is worn on the body and constantly monitors a patient's blood glucose levels. That data is uploaded to a handheld controller, smartphone, or smartwatch that provides information needed to keep blood glucose levels in a healthy range.

Image source: DexCom.

DexCom operates on a razor-and-blade business model. The permanent "razor" is the company's handheld device that receives and displays the data, while the disposable "blades" are its sensors that are inserted directly into a patient's body. After 10 days of use, they need to be properly tossed and replaced, thus providing a dependable source of recurring revenue.

This business model has allowed DexCom's top line to grow at a breakneck pace as it brings on new patients over time.

DXCM revenue (TTM). Data by YCharts.

Reasons for optimism

DexCom's revenue growth has been incredibly impressive, and it remains strong to this day. In 2018, its top line rose by 44%, sending it over the $1 billion mark.

Can the company keep its double-digit growth rate going? The odds look good for a number of reasons:

Dexcom has captured less than 20% of the 3.2 million patients in the U.S. who require intensive insulin therapy. The penetration rate looks even smaller when you factor in the international opportunity.  According to the company, several other groups of patients could benefit from CGM therapy. This includes people with gestational diabetes, those who require non-intensive insulin therapy, and intermittent CGM use in the hospital setting. Together, these opportunities add up to tens of millions of potential users in the U.S. alone.  Dexcom has struck up numerous partnerships with other diabetes companies like Tandem Diabetes Care, Insulet, Eli Lilly, and Novo Nordisk to help get the word out.  The company has teamed up with Alphabet's healthcare division, Verily, to develop a next-generation sensor, which aims to be smaller, cheaper, and fully disposable. 

Management forecasts that the company will pull in between $2 billion and $2.5 billion in total revenue by 2023 and improve profitability significantly. If those numbers prove to be anywhere close to accurate, shareholders should be nicely rewarded.

Reasons for caution

Dexcom would be a no-brainer investment if the company had the CGM market all to itself. Unfortunately, it faces a fair amount of competition. 

Its primary competitor is medical device giant Medtronic (NYSE:MDT), which has enjoyed a strong foothold in the diabetes market for decades, through its insulin pump division. It also launched a combination insulin pump/CGM system a few years ago, a device thath increased patient convenience and has proven quite popular with patients.

Another heavy hitter in the CGM space is Abbott Labs (NYSE:ABT), which won FDA approval for a CGM device called the Freestyle Libre in 2017. The Libre was the first CGM system that did not require its users to perform daily finger sticks for calibration, and was also marketed at a much lower price point than DexCom's CGM. The Freestyle Libre has experienced a lot of market success. 

Thus far, DexCom hasn't had any problems growing even with the competition from these well-funded giants, but it's possible that could change.

Another potential pitfall that could work against investors who buy today is Dexcom's generous valuation. The company is currently trading for more than 12 times sales and about 150 times next year's earnings estimates. Those figures suggest that Wall Street is pricing in a lot of growth. If it fails to deliver on its ambitious growth targets, shareholders could be in a for a world of hurt.

Is DexCom a buy?

While DexCom isn't an appropriate stock for risk-averse investors, I still think there is a lot like about the company. Its product is innovative, and the company has secured numerous partnership agreements, which should ensure it continues to win more than its fair share of the new business. What's more, the diabetes market is so huge that it could easily support multiple winners.

If you're a growth-focused investor who doesn't mind paying up for a high-growth business, DexCom could be a nice addition to your portfolio. 

Top 10 Bank Stocks To Own Right Now

tags:AP,CM,FCF,WFC,HSBA,

It’s really feeling like a dose of déjà vu for former fracking superstar Chesapeake Energy Corporation (NYSE:CHK). It was just a year or so ago, when many analysts and pundits thought CHK was careening towards filing for bankruptcy after the shale boom imploded and it was left with massive debts. And with oil prices drifting lower, CHK stock price is certainly acting like this is the potential outcome once again.

Top 10 Bank Stocks To Own Right Now: Ampco-Pittsburgh Corporation(AP)

Advisors' Opinion:

• [By ]

  The San Jose skyline Feb. 5, 2013. (Photo: AP)

  7. San Jose, California

  Median earnings increase between 2011 and 2016: 8.7 percent
  Workforce and earnings score: 53.4
  Final score: 47.4
  Overall rank: 19

• [By ]

  Mexico City (AP) -- A powerful magnitude-7.2 earthquake shook south and central Mexico Friday, causing people to flee swaying buildings and office towers in the country's capital, where residents were still jittery after a deadly quake five months ago.

• [By ]

  New York (AP) -- The bitter cold that followed a massive East Coast snowstorm should begin to lessen as temperatures inch up and climb past freezing next week, weather forecasters said.

Top 10 Bank Stocks To Own Right Now: Canadian Imperial Bank of Commerce(CM)

Advisors' Opinion:

• [By Lisa Levin] Companies Reporting Before The Bell Target Corporation (NYSE: TGT) is estimated to report quarterly earnings at $1.38 per share on revenue of $16.50 billion. Ralph Lauren Corporation (NYSE: RL) is expected to report quarterly earnings at $0.83 per share on revenue of $1.48 billion. Lowe's Companies, Inc. (NYSE: LOW) is projected to report quarterly earnings at $1.25 per share on revenue of $17.63 billion. Tiffany & Co. (NYSE: TIF) is estimated to report quarterly earnings at $0.83 per share on revenue of $957.49 million. Canadian Imperial Bank of Commerce (NYSE: CM) is expected to report quarterly earnings at $2.23 per share on revenue of $3.40 billion. Citi Trends, Inc. (NASDAQ: CTRN) is projected to report quarterly earnings at $0.9 per share on revenue of $210.70 million. Qiwi plc (NASDAQ: QIWI) is expected to report quarterly earnings at $0.25 per share on revenue of $60.19 million. iClick Interactive Asia Group Limited (NASDAQ: ICLK) is projected to report quarterly loss at $0.06 per share on revenue of $34.87 million.

   

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Canadian Imperial Bank of Commerce (CM)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Canadian Imperial Bank of Commerce (NYSE:CM) (TSE:CM) declared a quarterly dividend on Wednesday, May 23rd, Zacks reports. Stockholders of record on Thursday, June 28th will be paid a dividend of 1.036 per share by the bank on Friday, July 27th. This represents a $4.14 dividend on an annualized basis and a dividend yield of 4.63%. The ex-dividend date is Wednesday, June 27th.

• [By Motley Fool Transcribing]

  Canadian Imperial Bank of Commerce (NYSE:CM) Q1 2019 Earnings Conference CallFeb. 28, 2019 8:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

Top 10 Bank Stocks To Own Right Now: First Commonwealth Financial Corporation(FCF)

Advisors' Opinion:

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on First Commonwealth Financial (FCF)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on First Commonwealth Financial (FCF)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on First Commonwealth Financial (FCF)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  Get a free copy of the Zacks research report on First Commonwealth Financial (FCF)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  Get a free copy of the Zacks research report on First Commonwealth Financial (FCF)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on First Commonwealth Financial (FCF)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Bank Stocks To Own Right Now: Wells Fargo & Company(WFC)

Advisors' Opinion:

• [By ]

  Wells Fargo & Co. (WFC) , the U.S. bank already reeling from sanctions by regulators over alleged customer abuses, faces additional penalties of as much as $1 billion to resolve allegations over matters including auto insurance and mortgage-sales practices.

• [By Matthew Frankel]

  As far as positive surprises go, Wells Fargo (NYSE:WFC) was probably the biggest positive surprise. I probably don't have to tell most listeners, Wells Fargo hasn't had the best couple of years, when it comes to their fake accounts scandal, the fallout from that, the other mini scandals along the way, and just recently, their punishment by the same Federal Reserve that says they're not allowed to grow until they improve. They actually got the approval to buy back more than twice the amount of stock that they did last year. One, that says a lot about how well-capitalized they are. Two, it also says a lot that their management's willing to do that, that they think that their stock is at such a compelling bargain right now that they're willing to spend over $25 billion on buybacks alone.

• [By Jon C. Ogg]

  Wells Fargo & Company (NYSE: WFC) was valued at $26.4 billion, and the stake of 452.01 million shares is down slightly from the prior 456.5 million shares.

Top 10 Bank Stocks To Own Right Now: HSBC Holdings PLC (HSBA)

Advisors' Opinion:

• [By Ethan Ryder]

  HSBC (LON:HSBA) had its price target dropped by equities research analysts at Citigroup from GBX 810 ($10.78) to GBX 800 ($10.65) in a report released on Tuesday. The brokerage currently has a “buy” rating on the financial services provider’s stock. Citigroup’s price target points to a potential upside of 9.59% from the stock’s previous close.

• [By Joseph Griffin]

  HSBC (LON:HSBA) had its target price lowered by equities research analysts at Shore Capital from GBX 721 ($9.60) to GBX 625 ($8.32) in a report issued on Tuesday. The brokerage presently has a “sell” rating on the financial services provider’s stock. Shore Capital’s price objective indicates a potential downside of 14.71% from the company’s previous close.

• [By Max Byerly]

  HSBC (LON:HSBA) was upgraded by equities research analysts at Credit Suisse Group to a “neutral” rating in a research report issued to clients and investors on Thursday. The firm presently has a GBX 720 ($9.38) target price on the financial services provider’s stock, up from their previous target price of GBX 680 ($8.86). Credit Suisse Group’s price target suggests a potential upside of 5.82% from the company’s previous close.

• [By Stephan Byrd]

  Morgan Stanley set a GBX 855 ($10.91) price target on HSBC (LON:HSBA) in a research note issued to investors on Tuesday. The brokerage currently has a buy rating on the financial services provider’s stock.

Best Insurance Stocks To Invest In Right Now

tags:REIS,ATRS,SWZ,

When the masses descend upon snow-covered Davos for the World Economic Forum’s annual gathering, Esther Heldstab is determined to swim against the tide.

The purveyor of tourist mementos on the town’s main street is one of the few shopkeepers who won’t hand over their keys to multinational conglomerates who transform shoe stores and bakeries into lounges and cocktail party space for the week.

While the likes of Zurich Insurance, Credit Suisse and Deutsche Bank take over prime space on Promenade, Heldstab and her sister who run Swissalp Fantasy at no. 79 -- where the window display features a stuffed Bernese mountain dog -- simply stay put.

#lazy-img-322660176:before{padding-top:60.83333333333334%;}

“On this mile, you can pretty much ask what you want,” said Heldstab. No one interviewed for this story would speak on the record about rental costs, though Heldstab said should could double her money if she rented out her shop in a half-timber house festooned with Swiss crosses. Still, “it’s so nice when the people from all over the world come -- it’s like Hollywood.”

Best Insurance Stocks To Invest In Right Now: Reis, Inc(REIS)

Advisors' Opinion:

• [By Logan Wallace]

  Reis (NASDAQ:REIS) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

• [By Rich Smith]

  Shares of commercial real estate data provider Reis, Inc. (NASDAQ:REIS) soared 32.2% to close at $23 on the nose today, after Moody's Corporation (NYSE:MCO) announced it would acquire the company for (drumroll, please)...$23 a share!

• [By Shane Hupp]

  Emerald Expositions Events (NYSE: EEX) and Reis (NASDAQ:REIS) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

• [By Stephan Byrd]

  ValuEngine upgraded shares of Reis (NASDAQ:REIS) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

  Several other research analysts also recently commented on the company. Zacks Investment Research downgraded Reis from a hold rating to a strong sell rating in a research note on Friday, May 11th. BidaskClub raised Reis from a buy rating to a strong-buy rating in a research note on Friday, July 6th. Finally, B. Riley lowered their target price on Reis to $26.00 and set a buy rating for the company in a research note on Tuesday, May 8th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $22.00.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Reis (REIS)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Insurance Stocks To Invest In Right Now: Antares Pharma, Inc.(ATRS)

Advisors' Opinion:

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Antares Pharma (ATRS)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  Antares Pharma (NASDAQ:ATRS) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

• [By Shane Hupp]

  HC Wainwright set a $5.00 price objective on Antares Pharma (NASDAQ:ATRS) in a research report released on Friday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

• [By Logan Wallace]

  BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

• [By Stephan Byrd]

  Antares Pharma, Inc. (NASDAQ:ATRS) Director Jacques Gonella sold 300,000 shares of the firm’s stock in a transaction dated Wednesday, May 9th. The stock was sold at an average price of $2.47, for a total value of $741,000.00. Following the completion of the sale, the director now directly owns 11,936,413 shares of the company’s stock, valued at approximately $29,482,940.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

• [By Max Byerly]

  Antares Pharma (NASDAQ:ATRS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday.

Best Insurance Stocks To Invest In Right Now: Swiss Helvetia Fund, Inc. (SWZ)

Advisors' Opinion:

• [By Logan Wallace]

  Swiss Helvetia Fund, Inc. Common Stock (NYSE:SWZ) declared a Semi-Annual dividend on Tuesday, June 12th, Zacks reports. Investors of record on Friday, June 22nd will be paid a dividend of 0.203 per share by the closed-end fund on Friday, June 29th. The ex-dividend date of this dividend is Thursday, June 21st.

E-Cigs Really Do Help Smokers Quit, a New Study Shows

U.S. officials remain skeptical of electronic cigarettes' health benefits for smokers, but another study indicates the devices have real value.

The New England Journal of Medicine (NEJM) recently published the results of a very large study conducted in the U.K. by Queen Mary University of London that found e-cigs are twice as effective at helping people quit smoking as any other nicotine replacement therapy, such as nicotine patches, gum, lozenges, and inhalers -- an indication of the efficacy of e-cigs in fighting the smoking habit.

Image source: Getty Images.

Stamping out cigarettes

The study was the largest of its kind yet conducted, enrolling almost 900 people who wanted to quit smoking. Half of them were given electronic cigarettes; the other half got some other type of treatment.

Those given e-cigs got an initial starter pack and then had to buy supplies on their own. The nicotine replacement therapy users were given a broad choice of products, and were encouraged to use more than one if they wanted. Many did so, such as using a patch and gum together. They were also permitted to switch products during the trial.

According to the NEJM report, by the end of 52 weeks, 18% of those on e-cigs were still off cigarettes versus 9.9% of those on traditional smoking-cessation therapies. And even if they didn't quit smoking entirely, e-cig users were also more likely to have cut down on their smoking by 50% or more.

Other benefits from e-cig use included larger declines in the incidence of coughing and phlegm production, as well as less nausea, though e-cig users also reported more throat and mouth irritation. There was no real difference in either group with reports of wheezing or shortness of breath.

Digging its heels in

The Food and Drug Administration, however, has yet to find any e-cig to be safer than cigarettes, and as a result, U.S. healthcare providers are reluctant to recommend their use.

The American Academy of Family Physicians (AAFP) says that although the U.K. study seemed well designed, it still had shortcomings. The AAFP reiterated that it "does not endorse e-cigarettes as a cessation device," preferring instead to simply tell smokers they should stop smoking and use FDA-approved therapies. The American Lung Association says, "We only support methods that are FDA approved and regulated."

With the FDA grumbling that it might impose harsh new restrictions on e-cig makers, especially after Altria (NYSE:MO) invested in leading manufacturer Juul Labs, there's enough reason to think it will be a long time before the U.S. medical community ever gets on board.

That's not the case in the U.K., where there is mounting evidence that e-cigs may be the best available smoking alternative. Previously, the government agency Public Health England said e-cigs are 95% safer than traditional cigarettes and has called for them to be made available through the U.K.'s National Health Service within five years.

Not a complete vindication

An important caveat to the study -- and what perhaps gave the AAFP pause about endorsing the findings -- was that while electronic cigarettes were more effective at helping wean smokers off cigarettes, it came as a result of being accompanied by appropriate "behavioral support," such as counseling (the other group received support as well), which AAFP says is not how real-world e-cig smokers use the product. Also, the e-cigs that were used typically had lower levels of nicotine in them than other commercial e-cigs on the market.

Critics also contend e-cigs merely substitute one addiction for another. At the end of the one-year study, 80% of those in the e-cig group who had quit smoking were still using the devices, while just 9% of those in the group using other means of cessation were still on them.

National Public Radio (NPR), however, quotes the study's author Peter Hajek as saying that despite more people continuing to use e-cigs after quitting, it is easier to quit vaping than it is to quit smoking. Nicotine addiction is an issue, but the risks are lower than with tobacco use. "So from our point of view ... this is not a public health issue anymore," Hajek said.

Because the FDA remains more concerned about minors' use of electronic cigarettes than getting adults to quit smoking, policy decisions in the U.S. may not be as favorable for e-cigs as those made in the U.K. E-cigs may still end up being allowed here, but without a stamp of approval from regulators.

Deutsche Bank Analysts Give Xing (O1BC) a €329.00 Price Target

Deutsche Bank set a €329.00 ($382.56) target price on Xing (ETR:O1BC) in a research report released on Thursday morning. The firm currently has a buy rating on the stock.

A number of other research firms also recently weighed in on O1BC. Berenberg Bank set a €290.00 ($337.21) price target on shares of Xing and gave the stock a neutral rating in a research note on Wednesday, February 27th. Hauck & Aufhaeuser set a €310.00 ($360.47) price target on shares of Xing and gave the stock a buy rating in a research note on Thursday, November 1st. Commerzbank set a €290.00 ($337.21) price target on shares of Xing and gave the stock a neutral rating in a research note on Wednesday, November 7th. Finally, equinet set a €305.00 ($354.65) price target on shares of Xing and gave the stock a buy rating in a research note on Wednesday, November 7th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of €306.00 ($355.81).

Get Xing alerts:

Shares of Xing stock opened at €304.50 ($354.07) on Thursday. Xing has a 12 month low of €189.40 ($220.23) and a 12 month high of €297.00 ($345.35).

Xing Company Profile

Xing SE operates professional networking Websites primarily in Germany, Austria, Switzerland, and internationally. It operates through four segments: B2C, B2B E-Recruiting, B2B Advertising & Events, and Kununu International. The B2C segment serves XING members who use XING.com, XING Jobs, and kununu.com to network with other professionals for finding a suitable job, obtaining information about employers, or reading about career-related topics.

Recommended Story: Short Selling Stocks and Day Traders

Unbitcoin Plays

&l;p&g;The February 28 issue of Forbes profiles a computer scientist who aims to make the world of crypto transactions more transparent (&l;a href=&q;https://www.forbes.com/sites/michaeldelcastillo/2019/02/04/navigating-bitcoin-ethereum-xrp-how-google-is-quietly-making-blockchains-searchable/&q;&g;&l;em&g;Googling Blockchain&l;/em&g;&l;/a&g;). How does an investor make a bet in this turbulent field?

More searching and more transparency are not going to save bitcoin, which, helpful as it might be for tax evaders and drug importers, is next to useless for everyday transactions. The search for winners in a world of digital money should, instead, veer more into the mainstream.

&l;strong&g; Mastercard (MA)&l;/strong&g;, &l;strong&g;Visa (V)&l;/strong&g; and &l;strong&g;PayPal (PYPL)&l;/strong&g; are obvious candidates. Near-field communication makes &l;strong&g;Apple (AAPL)&l;/strong&g;, with Apple Pay and &l;strong&g;Alphabet (GOOG)&l;/strong&g;, with Google Pay, into banks. &l;strong&g;JPMorgan Chase (JPM)&l;/strong&g; is getting good at digital wallets. Finally, I see &l;strong&g;BlackRock (BLK)&l;/strong&g; as a potential issuer of digital cash; someday, when inflation returns, it could compete with the U.S. dollar with an iShares blending gold and Treasury bills.&l;/p&g;

Intercept Pharmaceuticals Inc (ICPT) Files 10-K for the Fiscal Year Ended on December 31, 2018

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need. Intercept Pharmaceuticals Inc has a market cap of $3.16 billion; its shares were traded at around $106.69 with and P/S ratio of 17.79.

For the last quarter Intercept Pharmaceuticals Inc reported a revenue of $53.3 million, compared with the revenue of $37.69 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $179.8 million, an increase of 37.3% from last year. For the last five years Intercept Pharmaceuticals Inc had an average revenue growth rate of 202.1% a year.

The reported loss per diluted share was $10.86 for the year, compared with the loss per share of $13.63 in the previous year. The Intercept Pharmaceuticals Inc had an operating margin of -158.78%, compared with the operating margin of -256.28% a year before. The 10-year historical median operating margin of Intercept Pharmaceuticals Inc is -1613.31%. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, Intercept Pharmaceuticals Inc has the cash and cash equivalents of $436.2 million, compared with $70.0 million in the previous year. The company had no long term debt, compared with $355.7 million in the previous year. Intercept Pharmaceuticals Inc has a financial strength rank of 4 (out of 10).

At the current stock price of $106.69, Intercept Pharmaceuticals Inc is traded at 95.8% discount to its historical median P/S valuation band of $2533.32. The P/S ratio of the stock is 17.79, while the historical median P/S ratio is 422.36. The stock gained 80.89% during the past 12 months.

Directors and Officers Recent Trades:

EVP, Research & Development Christian Weyer sold 333 shares of ICPT stock on 03/01/2019 at the average price of $103.16. The price of the stock has increased by 3.42% since.Chief Medical Officer David Shapiro sold 2,000 shares of ICPT stock on 03/01/2019 at the average price of $103.16. The price of the stock has increased by 3.42% since.Director Srinivas Akkaraju sold 23,438 shares of ICPT stock on 02/19/2019 at the average price of $128.78. The price of the stock has decreased by 17.15% since.Chief Medical Officer David Shapiro sold 2,000 shares of ICPT stock on 02/15/2019 at the average price of $111.51. The price of the stock has decreased by 4.32% since.

For the complete 20-year historical financial data of ICPT, click here.